Aurobindo's Veritaz acquisition unlikely to add much value: Analysts

Deal is nonetheless a stepping stone in the drug firm's strategic plan to focus on domestic formulations market, where it aims to have Rs 1,000-cr sales in three years

Aurobindo Pharma

Aurobindo Pharma | Photo: Wikipedia

Hyderabad-based Aurobindo Pharma’s Rs 171 crore acquisition of Veritaz Healthcare is unlikely to add much value to its business. It is nonetheless a stepping stone in the drug firm’s strategic

Also Read

Aurobindo Pharma acquires Veritaz' domestic business for Rs 171 cr

Strong product pipeline, valuations keep street positive on Aurobindo

N Govindarajan steps down as Aurobindo Pharma managing director

Byju's continues acquisition spree, buys Austrian math-learning co GeoGebra

TMS Ep58: Privatisation, Google smartwatch, RBI rates, encryption

NCDEX, IPFT launch call centre to create awareness about agri-derivatives

Fertilizer shares in demand, zoom up to 20% amid supply worries

India's oldest bourse BSE searches for CEO as Ashish Chauhan's term ends

Ruchi Soya, Brightcom, Adani Power: How to trade buzzing stocks of the day?

Adani Power up 12%, hits 52-week high on heavy volume; zooms 37% in 6 days

First Published: Mar 29 2022 | 4:42 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to